E
Harvard Bioscience, Inc.
HBIO
$0.7754
$0.00150.19%
E
Sell
11/11/2024Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 11/11/2024 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.55 to 0.6.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 11/11/2024 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.55 to 0.6.
D
Sell
10/25/2024Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 10/25/2024 due to an increase in the volatility index and valuation index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 10/25/2024 due to an increase in the volatility index and valuation index.
E
Sell
9/24/2024Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index and total return index.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index and total return index.
D
Sell
9/6/2024Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 9/6/2024 due to an increase in the volatility index and valuation index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 9/6/2024 due to an increase in the volatility index and valuation index.
E
Sell
8/2/2024Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 8/2/2024 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 358.1% from $883 to -$2.28M, earnings per share declined from -$0.0426 to -$0.11, and operating cash flow declined 67.39% from $4.3M to $1.4M.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 8/2/2024 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 358.1% from $883 to -$2.28M, earnings per share declined from -$0.0426 to -$0.11, and operating cash flow declined 67.39% from $4.3M to $1.4M.
D
Sell
4/1/2024Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 4/1/2024 due to a major increase in the growth index and volatility index. EBIT increased 194.64% from -$933 to $883, and total revenue increased 11% from $25.36M to $28.15M.
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 4/1/2024 due to a major increase in the growth index and volatility index. EBIT increased 194.64% from -$933 to $883, and total revenue increased 11% from $25.36M to $28.15M.
E
Sell
2/16/2024Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 2/16/2024 due to a decline in the volatility index and total return index.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 2/16/2024 due to a decline in the volatility index and total return index.
D
Sell
2/1/2024Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 2/1/2024 due to an increase in the total return index and volatility index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 2/1/2024 due to an increase in the total return index and volatility index.
E
Sell
1/9/2024Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index.
D
Sell
12/14/2023Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 12/14/2023 due to an increase in the volatility index and total return index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D- from E+ on 12/14/2023 due to an increase in the volatility index and total return index.
E
Sell
11/29/2023Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 11/29/2023 due to a decline in the volatility index and valuation index.
Harvard Bioscience, Inc. (HBIO) was downgraded to E+ from D- on 11/29/2023 due to a decline in the volatility index and valuation index.
D
Sell
3/27/2023Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 3/27/2023 due to a decline in the valuation index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 3/27/2023 due to a decline in the valuation index.
D
Sell
3/10/2023Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 3/10/2023 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 312.79% from $649 to $2.68M, EBIT increased 102.31% from -$2.43M to $56, and earnings per share increased from -$0.0818 to -$0.0396.
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 3/10/2023 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 312.79% from $649 to $2.68M, EBIT increased 102.31% from -$2.43M to $56, and earnings per share increased from -$0.0818 to -$0.0396.
D
Sell
11/14/2022Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 11/14/2022 due to a substantial decline in the total return index, volatility index and growth index. Earnings per share declined from $0.059 to -$0.0818, EBIT declined 174.94% from -$882 to -$2.43M, and total revenue declined 7.83% from $29.21M to $26.92M.
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 11/14/2022 due to a substantial decline in the total return index, volatility index and growth index. Earnings per share declined from $0.059 to -$0.0818, EBIT declined 174.94% from -$882 to -$2.43M, and total revenue declined 7.83% from $29.21M to $26.92M.
D
Sell
5/6/2022Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 5/6/2022 due to an increase in the valuation index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 5/6/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index and volatility index. EBIT declined 34.72% from $648 to $423.
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 4/20/2022 due to a major decline in the growth index and volatility index. EBIT declined 34.72% from $648 to $423.
D
Sell
2/9/2022Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 2/9/2022 due to a decline in the total return index and volatility index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 2/9/2022 due to a decline in the total return index and volatility index.
D
Sell
1/12/2022Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/12/2022 due to an increase in the valuation index and volatility index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/12/2022 due to an increase in the valuation index and volatility index.
D
Sell
12/22/2021Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 12/22/2021 due to a decline in the valuation index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 12/22/2021 due to a decline in the valuation index.
D
Sell
12/7/2021Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 12/7/2021 due to an increase in the valuation index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 12/7/2021 due to an increase in the valuation index.
D
Sell
11/23/2021Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Operating cash flow declined 185.94% from $768 to -$660, and EBIT declined 14.51% from $758 to $648.
Harvard Bioscience, Inc. (HBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Operating cash flow declined 185.94% from $768 to -$660, and EBIT declined 14.51% from $758 to $648.
D
Sell
11/3/2021Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 11/3/2021 due to a decline in the valuation index and volatility index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 11/3/2021 due to a decline in the valuation index and volatility index.
D
Sell
10/8/2021Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 10/8/2021 due to a large increase in the growth index, solvency index and volatility index. EBIT increased 141.4% from $314 to $758, earnings per share increased from -$0.02 to -$0.0102, and total revenue increased 8.18% from $26.99M to $29.2M.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 10/8/2021 due to a large increase in the growth index, solvency index and volatility index. EBIT increased 141.4% from $314 to $758, earnings per share increased from -$0.02 to -$0.0102, and total revenue increased 8.18% from $26.99M to $29.2M.
D
Sell
5/11/2021Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 5/11/2021 due to a decline in the valuation index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 5/11/2021 due to a decline in the valuation index.
D
Sell
1/14/2021Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/14/2021 due to a large increase in the total return index, volatility index and valuation index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/14/2021 due to a large increase in the total return index, volatility index and valuation index.
D
Sell
3/16/2020Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 3/16/2020 due to a decline in the volatility index and total return index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 3/16/2020 due to a decline in the volatility index and total return index.
D
Sell
11/13/2019Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D+ from C- on 11/13/2019 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 960.73% from -$247 to -$2.62M, earnings per share declined from -$0.01 to -$0.07, and EBIT declined 138.58% from $1.17M to -$451.
Harvard Bioscience, Inc. (HBIO) was downgraded to D+ from C- on 11/13/2019 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 960.73% from -$247 to -$2.62M, earnings per share declined from -$0.01 to -$0.07, and EBIT declined 138.58% from $1.17M to -$451.
C
Hold
10/23/2019Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to C- from D+ on 10/23/2019 due to a noticeable increase in the volatility index and total return index.
Harvard Bioscience, Inc. (HBIO) was upgraded to C- from D+ on 10/23/2019 due to a noticeable increase in the volatility index and total return index.
D
Sell
8/14/2019Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 8/14/2019 due to a substantial increase in the growth index, solvency index and efficiency index. EBIT increased 3,338.24% from $34 to $1.17M, net income increased 89.58% from -$2.37M to -$247, and earnings per share increased from -$0.063 to -$0.01.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 8/14/2019 due to a substantial increase in the growth index, solvency index and efficiency index. EBIT increased 3,338.24% from $34 to $1.17M, net income increased 89.58% from -$2.37M to -$247, and earnings per share increased from -$0.063 to -$0.01.
D
Sell
6/5/2019Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 6/5/2019 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.52 to 1.12, and debt to equity increased from 0.73 to 0.85.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 6/5/2019 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.52 to 1.12, and debt to equity increased from 0.73 to 0.85.
D
Sell
4/25/2019Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 4/25/2019 due to an increase in the growth index, efficiency index and volatility index. Net income increased 1,217.97% from -$256 to $2.86M, earnings per share increased from -$0.01 to $0.0733, and operating cash flow increased 280.82% from -$1.43M to $2.59M.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 4/25/2019 due to an increase in the growth index, efficiency index and volatility index. Net income increased 1,217.97% from -$256 to $2.86M, earnings per share increased from -$0.01 to $0.0733, and operating cash flow increased 280.82% from -$1.43M to $2.59M.
D
Sell
12/7/2018Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 12/7/2018 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 212.29% from $1.28M to -$1.43M, EBIT declined 51.05% from $1.82M to $890, and total revenue declined 9.16% from $31.52M to $28.64M.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 12/7/2018 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 212.29% from $1.28M to -$1.43M, EBIT declined 51.05% from $1.82M to $890, and total revenue declined 9.16% from $31.52M to $28.64M.
D
Sell
9/26/2018Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D+ from C- on 9/26/2018 due to a decline in the total return index.
Harvard Bioscience, Inc. (HBIO) was downgraded to D+ from C- on 9/26/2018 due to a decline in the total return index.
C
Hold
8/15/2018Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to C- from D+ on 8/15/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 676.92% from $234 to $1.82M, operating cash flow increased 185.04% from $448 to $1.28M, and earnings per share increased from -$0.1146 to -$0.0406.
Harvard Bioscience, Inc. (HBIO) was upgraded to C- from D+ on 8/15/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 676.92% from $234 to $1.82M, operating cash flow increased 185.04% from $448 to $1.28M, and earnings per share increased from -$0.1146 to -$0.0406.
D
Sell
1/5/2018Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/5/2018 due to an increase in the volatility index, total return index and solvency index.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 1/5/2018 due to an increase in the volatility index, total return index and solvency index.
D
Sell
11/7/2017Downgrade
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 11/7/2017 due to a noticeable decline in the growth index, volatility index and valuation index. EBIT declined 13,700% from $1 to -$136, earnings per share declined from -$0.011 to -$0.012, and total revenue declined 0.65% from $25.21M to $25.05M.
Harvard Bioscience, Inc. (HBIO) was downgraded to D from D+ on 11/7/2017 due to a noticeable decline in the growth index, volatility index and valuation index. EBIT declined 13,700% from $1 to -$136, earnings per share declined from -$0.011 to -$0.012, and total revenue declined 0.65% from $25.21M to $25.05M.
D
Sell
9/21/2017Upgraded
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 9/21/2017 due to a substantial increase in the growth index, volatility index and total return index. Operating cash flow increased 177.87% from -$610 to $475, EBIT increased 100.16% from -$639 to $1, and earnings per share increased from -$0.0308 to -$0.011.
Harvard Bioscience, Inc. (HBIO) was upgraded to D+ from D on 9/21/2017 due to a substantial increase in the growth index, volatility index and total return index. Operating cash flow increased 177.87% from -$610 to $475, EBIT increased 100.16% from -$639 to $1, and earnings per share increased from -$0.0308 to -$0.011.
D
Sell
3/11/2016Downgrade
Harvard Bioscience Inc. (HBIO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 360.78% from $153 to -$399, earnings per share declined from $0.01 to -$0.025, and total revenue declined 10.66% from $28.8M to $25.73M.
Harvard Bioscience Inc. (HBIO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 360.78% from $153 to -$399, earnings per share declined from $0.01 to -$0.025, and total revenue declined 10.66% from $28.8M to $25.73M.
D
Sell
8/28/2015Downgrade
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 8/28/2015 due to a decline in the total return index and volatility index.
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 8/28/2015 due to a decline in the total return index and volatility index.
C
Hold
8/10/2015Upgraded
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 8/10/2015 due to an increase in the growth index and solvency index. Total revenue increased 11.79% from $25.76M to $28.8M, and debt to equity declined from 0.24 to 0.22.
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 8/10/2015 due to an increase in the growth index and solvency index. Total revenue increased 11.79% from $25.76M to $28.8M, and debt to equity declined from 0.24 to 0.22.
D
Sell
8/6/2015Downgrade
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 8/6/2015 due to a significant decline in the volatility index, solvency index and total return index.
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 8/6/2015 due to a significant decline in the volatility index, solvency index and total return index.
C
Hold
5/15/2015Downgrade
Harvard Bioscience Inc. (HBIO) was downgraded to C- from C on 5/15/2015 due to a noticeable decline in the growth index, valuation index and efficiency index. EBIT declined 154.95% from $1.99M to -$1.09M, operating cash flow declined 139.35% from $1.26M to -$497, and total revenue declined 15.15% from $30.36M to $25.76M.
Harvard Bioscience Inc. (HBIO) was downgraded to C- from C on 5/15/2015 due to a noticeable decline in the growth index, valuation index and efficiency index. EBIT declined 154.95% from $1.99M to -$1.09M, operating cash flow declined 139.35% from $1.26M to -$497, and total revenue declined 15.15% from $30.36M to $25.76M.
C
Hold
12/19/2014Upgraded
Harvard Bioscience Inc. (HBIO) was upgraded to C from C- on 12/19/2014 due to an increase in the volatility index, valuation index and efficiency index.
Harvard Bioscience Inc. (HBIO) was upgraded to C from C- on 12/19/2014 due to an increase in the volatility index, valuation index and efficiency index.
C
Hold
9/17/2014Upgraded
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 9/17/2014 due to a noticeable increase in the growth index. Earnings per share increased from $0.02 to $0.03, operating cash flow increased 31.9% from $1.07M to $1.41M, and EBIT increased 25.97% from $1.47M to $1.85M.
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 9/17/2014 due to a noticeable increase in the growth index. Earnings per share increased from $0.02 to $0.03, operating cash flow increased 31.9% from $1.07M to $1.41M, and EBIT increased 25.97% from $1.47M to $1.85M.
D
Sell
4/8/2014Downgrade
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 4/8/2014 due to a decline in the total return index, growth index and volatility index.
Harvard Bioscience Inc. (HBIO) was downgraded to D+ from C- on 4/8/2014 due to a decline in the total return index, growth index and volatility index.
C
Hold
3/24/2014Upgraded
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 3/24/2014 due to a noticeable increase in the growth index and volatility index. Total revenue increased 10.81% from $25.14M to $27.85M.
Harvard Bioscience Inc. (HBIO) was upgraded to C- from D+ on 3/24/2014 due to a noticeable increase in the growth index and volatility index. Total revenue increased 10.81% from $25.14M to $27.85M.
NASDAQ
03/11/2025 12:33PM Eastern
Quotes delayed
